Xiang Jing
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiang Jing has a total of 335 co-authors. Here are the top co-authors by number of shared publications:
Jianmin Ding
Department of Ultrasound, Tianjin Third Central Hospital
18 shared publicationsYan Zhou
Department of Ultrasound, Tianjin Third Central Hospital
18 shared publicationsHongyu Zhou
12 shared publicationsYandong Wang
Department of Ultrasound, Tianjin Third Central Hospital, Tianjin 300170, China; Tianjin Institute of Hepatobiliary Disease, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Third Central Hospital, Tianjin 300170, China
11 shared publications- Ping Liang
Department of Interventional Ultrasound, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China
7 shared publications Fengmei Wang
Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital, Tianjin Institute of Hepatobiliary Disease, Tianjin Key Laboratory of Artificial Cell, Artificial Cell Engineering Technology Research Center of Public Health Ministry, Tianjin, China
6 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Wiley in Journal of Magnetic Resonance Imaging
Simplifying CT / MRI LI ‐ RADS v2018 Maintains Diagnostic Performance: An Individual Participant Data Meta‐Analysis
Background: The Liver Imaging Reporting and Data System (LI‐RADS) diagnostic algorithm assesses hepatocellular carcinoma (HCC) probability of liver observations in high‐risk individuals, but complexity may limit its adoption. Purpose: To evaluate whether LI‐RADS v2018 can be simplified without impairing diagnostic performance by removing threshold growth (TG) and reducing size cut‐offs. Study Type: Retrospective meta‐analysis. Population: Eight thousand five hundred eighty‐two patients (mean age: 59 ± 11 years; 6610 male) at risk for HCC with CT/MRI (986 CT, 6554 MRI, and 1042 CT/MRI). Field Strength/Sequence: Field strength: 1.5T and 3.0T; sequences varied by institution per LI‐RADS technical requirements. Assessment: LI‐RADS v2018 using major features only was compared with seven simplifications removing TG and/or applying single size cut‐offs (≥ 10, ≥ 15, and ≥ 20 mm) in individual participant data (IPD) of 64 studies (29 institutions, 11 countries) from the LI‐RADS Living Systematic Review and IPD Meta‐analysis Project. Risk of bias was assessed with QUADAS‐2. Statistical Tests: Summary receiver operating characteristic curves estimated area under the curve (AUC) across LR‐3 to LR‐5; LR‐5 sensitivity, specificity, and positive predictive value (PPV) were estimated using a one‐step bivariate mixed‐effects model. Differences were assessed by cluster bootstrap. p < 0.05 indicated significance, uncorrected for multiple comparisons. Results: Nine thousand four hundred six observations were included. Excluding TG with a 10‐mm cut‐off showed AUC similar to LI‐RADS v2018 (0.80 vs. 0.81, p = 0.44) and significantly higher LR‐5 sensitivity (73.8% vs. 71.8%) with similar specificity (72.5% vs. 73.7%, p = 0.13) and PPV (97.8% vs. 97.8%, p = 0.73). Removing TG with 15‐mm and 20‐mm cut‐offs had significantly lower AUC than v2018 (−0.03 [95% CI: −0.041, −0.019]; −0.043 [−0.054, −0.032], respectively) and sensitivity (−13.2% [95% CI: −14.5%, −12.0%]; −30.1% [−31.7%, −28.5%], respectively). Of the 64 studies, 17 had low‐risk of bias, and 56 had low applicability concerns. Conclusion: Simplifying LI‐RADS v2018 by removing TG and using a 10‐mm size cut‐off preserved diagnostic table AUC while improving LR‐5 sensitivity without loss of specificity or PPV. Protocol Registration: Open Science Framework ( https://osf.io/cjwgp ). Evidence Level: 3. Technical Efficiency: Stage 2.
- 2 November 2026
- Published by Wiley in Journal of Magnetic Resonance Imaging
Open AccessSimplifying CT / MRI LI ‐ RADS v2018 Maintains Diagnostic Performance: An Individual Participant Data Meta‐Analysis
Background: The Liver Imaging Reporting and Data System (LI‐RADS) diagnostic algorithm assesses hepatocellular carcinoma (HCC) probability of liver observations in high‐risk individuals, but complexity may limit its adoption. Purpose: To evaluate whether LI‐RADS v2018 can be simplified without impairing diagnostic performance by removing threshold growth (TG) and reducing size cut‐offs. Study Type: Retrospective meta‐analysis. Population: Eight thousand five hundred eighty‐two patients (mean age: 59 ± 11 years; 6610 male) at risk for HCC with CT/MRI (986 CT, 6554 MRI, and 1042 CT/MRI). Field Strength/Sequence: Field strength: 1.5T and 3.0T; sequences varied by institution per LI‐RADS technical requirements. Assessment: LI‐RADS v2018 using major features only was compared with seven simplifications removing TG and/or applying single size cut‐offs (≥ 10, ≥ 15, and ≥ 20 mm) in individual participant data (IPD) of 64 studies (29 institutions, 11 countries) from the LI‐RADS Living Systematic Review and IPD Meta‐analysis Project. Risk of bias was assessed with QUADAS‐2. Statistical Tests: Summary receiver operating characteristic curves estimated area under the curve (AUC) across LR‐3 to LR‐5; LR‐5 sensitivity, specificity, and positive predictive value (PPV) were estimated using a one‐step bivariate mixed‐effects model. Differences were assessed by cluster bootstrap. p < 0.05 indicated significance, uncorrected for multiple comparisons. Results: Nine thousand four hundred six observations were included. Excluding TG with a 10‐mm cut‐off showed AUC similar to LI‐RADS v2018 (0.80 vs. 0.81, p = 0.44) and significantly higher LR‐5 sensitivity (73.8% vs. 71.8%) with similar specificity (72.5% vs. 73.7%, p = 0.13) and PPV (97.8% vs. 97.8%, p = 0.73). Removing TG with 15‐mm and 20‐mm cut‐offs had significantly lower AUC than v2018 (−0.03 [95% CI: −0.041, −0.019]; −0.043 [−0.054, −0.032], respectively) and sensitivity (−13.2% [95% CI: −14.5%, −12.0%]; −30.1% [−31.7%, −28.5%], respectively). Of the 64 studies, 17 had low‐risk of bias, and 56 had low applicability concerns. Conclusion: Simplifying LI‐RADS v2018 by removing TG and using a 10‐mm size cut‐off preserved diagnostic table AUC while improving LR‐5 sensitivity without loss of specificity or PPV. Protocol Registration: Open Science Framework ( https://osf.io/cjwgp ). Evidence Level: 3. Technical Efficiency: Stage 2.
- Open Access
- 17 June 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1849758
The aMAP score improves discrimination of prognostic models in hepatocellular carcinoma after radiofrequency ablation
Purpose: The aMAP score has proven a reliable model for predicting the risk of hepatocellular carcinoma (HCC) development in patients with various types of hepatitis, but its value in predicting recurrence in HCC patients after radiofrequency ablation (RFA) remains unclear. This study aims to assess the utility of the aMAP score for predicting recurrence in HCC patients after RFA. Methods: The retrospective analysis included 350 firstly diagnosed HCC patients who underwent RFA. Survival analysis was performed using Kaplan-Meier curves with the log-rank test. Cox regression analysis was conducted to assess the prognostic value of aMAP score. The Fine-Gray method was adopted for sensitivity analysis. Subgroup analyses verified the consistency of the aMAP score’s predictive value. C-index, net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were used to evaluate its incremental predictive value. Results: Among 350 patients undergoing RFA, a total of 197 (56.3%) patients had a low aMAP score (≤ 63.55), and 153 patients (43.7%) had a high aMAP score (> 63.55). Patients with low aMAP scores exhibited significantly longer recurrence-free survival (RFS) ( p = 0.016). Multivariate analysis confirmed that the aMAP score is an independent prognostic factor for RFS ( HR = 1.40, p = 0.028). Furthermore, when incorporated into a tumor-related characteristics model (tumor number and size of largest tumor), the aMAP score provided significant incremental value in predicting RFS (IDI 2.6%, p = 0.036; NRI 15.9%, p = 0.036). Conclusions: The aMAP score is a potentially predictor for HCC patients undergoing RFA. Incorporation of the aMAP score into the prediction model improved its predictive accuracy.
- 17 June 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1849758
Open AccessThe aMAP score improves discrimination of prognostic models in hepatocellular carcinoma after radiofrequency ablation
Purpose: The aMAP score has proven a reliable model for predicting the risk of hepatocellular carcinoma (HCC) development in patients with various types of hepatitis, but its value in predicting recurrence in HCC patients after radiofrequency ablation (RFA) remains unclear. This study aims to assess the utility of the aMAP score for predicting recurrence in HCC patients after RFA. Methods: The retrospective analysis included 350 firstly diagnosed HCC patients who underwent RFA. Survival analysis was performed using Kaplan-Meier curves with the log-rank test. Cox regression analysis was conducted to assess the prognostic value of aMAP score. The Fine-Gray method was adopted for sensitivity analysis. Subgroup analyses verified the consistency of the aMAP score’s predictive value. C-index, net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were used to evaluate its incremental predictive value. Results: Among 350 patients undergoing RFA, a total of 197 (56.3%) patients had a low aMAP score (≤ 63.55), and 153 patients (43.7%) had a high aMAP score (> 63.55). Patients with low aMAP scores exhibited significantly longer recurrence-free survival (RFS) ( p = 0.016). Multivariate analysis confirmed that the aMAP score is an independent prognostic factor for RFS ( HR = 1.40, p = 0.028). Furthermore, when incorporated into a tumor-related characteristics model (tumor number and size of largest tumor), the aMAP score provided significant incremental value in predicting RFS (IDI 2.6%, p = 0.036; NRI 15.9%, p = 0.036). Conclusions: The aMAP score is a potentially predictor for HCC patients undergoing RFA. Incorporation of the aMAP score into the prediction model improved its predictive accuracy.
- Open Access
- 15 October 2025
- Published by Springer Nature in International Journal of Computer Assisted Radiology and Surgery
- Vol. 21 (2) , 441
Correction: Semi-automatic puncture robotic system based on real-time multi-modal image fusion: preclinical evaluation
- 15 October 2025
- Published by Springer Nature in International Journal of Computer Assisted Radiology and Surgery
- Vol. 21 (2) , 441
Open AccessCorrection: Semi-automatic puncture robotic system based on real-time multi-modal image fusion: preclinical evaluation
- Open Access
- 10 September 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 55-70
Expert consensus regarding the clinical application of liver contrast-enhanced US with Sonazoid (Sonazoid CEUS)
Sonazoid, a combined blood pool and Kupffer-cell agent, can be specifically phagocytosed by Kupffer cells in the liver, allowing lesion detection and characterization of focal liver lesions (FLLs) at the post-vascular phase, apart from the vascular phase, which is similar to that of other second-generation ultasound (US) contrast agents. Sonazoid contrast-enhanced US (CEUS) is currently approved for use in some Asian countries. With the increasing use of Sonazoid CEUS for FLLs in clinical practice, developing consensus or guidelines to help standardize its use is required. The expert consensus aimed to review recent evidence and make evidence-based recommendations for radiologists and clinicians involved in the management of liver diseases regarding the use of Sonazoid CEUS in the surveillance or detection, characterization of FLLs, CEUS for interventional and intraoperative use, and tumor treatment response evaluation in patients with FLLs. This consensus was conducted without using artificial intelligence tools in accordance with the TITAN Guidelines 2025.
- 10 September 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (1) , 55-70
Open AccessExpert consensus regarding the clinical application of liver contrast-enhanced US with Sonazoid (Sonazoid CEUS)
Sonazoid, a combined blood pool and Kupffer-cell agent, can be specifically phagocytosed by Kupffer cells in the liver, allowing lesion detection and characterization of focal liver lesions (FLLs) at the post-vascular phase, apart from the vascular phase, which is similar to that of other second-generation ultasound (US) contrast agents. Sonazoid contrast-enhanced US (CEUS) is currently approved for use in some Asian countries. With the increasing use of Sonazoid CEUS for FLLs in clinical practice, developing consensus or guidelines to help standardize its use is required. The expert consensus aimed to review recent evidence and make evidence-based recommendations for radiologists and clinicians involved in the management of liver diseases regarding the use of Sonazoid CEUS in the surveillance or detection, characterization of FLLs, CEUS for interventional and intraoperative use, and tumor treatment response evaluation in patients with FLLs. This consensus was conducted without using artificial intelligence tools in accordance with the TITAN Guidelines 2025.
- Open Access
- 14 August 2025
- Published by Springer Nature in International Journal of Computer Assisted Radiology and Surgery
- Vol. 20 (12) , 2479-2489
Semi-automatic puncture robotic system based on real-time multi-modal image fusion: preclinical evaluation
Purpose: Traditional surgical robot system relying on computed tomography (CT) navigation suffers from two drawbacks during abdominal organ puncture surgeries. Firstly, the puncture target is displaced under the influence of respiration, thereby reducing the puncture accuracy. Secondly, the puncture process lacks real-time visualization, which may potentially give rise to medical accidents. This paper presents a semi-automatic surgical robot system based on the fusion guidance of real-time ultrasound images and CT, along with the monitoring of the patient’s respiratory state, to address these issues. Method: This system utilizes a six-axis force sensor in contact with the human body, and a respiratory model can be constructed through data got from force sensor to monitor the patient’s respiratory phase and recommend the optimal puncture phase. The issue of non-real-time puncture guidance is addressed through the real-time registration and fusion of ultrasound (US) images with preoperative CT images. Results: Phantom experiments and animal experiments were carried out based on this design. The test results indicate that in these two experiments, the average fusion error between US and CT of the main tissues in the liver is within 3 mm. For puncture accuracy, in the phantom experiment, the average puncture error was 1.0 mm, with a minimum of 0 mm and a maximum of 2.1 mm. In the animal experiment, the average puncture error was 2.5 mm, ranging from a minimum of 1.6 mm to a maximum of 3.0 mm. Conclusion: The results of two experiments show both the image fusion accuracy and puncture accuracy of this system are within 3mm, which can meet the requirement of 5 mm puncture accuracy in clinical practice. Approximately 70% of the operation are automatically accomplished by robot system, greatly reducing the reliance on the doctor’s experience.
- 14 August 2025
- Published by Springer Nature in International Journal of Computer Assisted Radiology and Surgery
- Vol. 20 (12) , 2479-2489
Open AccessSemi-automatic puncture robotic system based on real-time multi-modal image fusion: preclinical evaluation
Purpose: Traditional surgical robot system relying on computed tomography (CT) navigation suffers from two drawbacks during abdominal organ puncture surgeries. Firstly, the puncture target is displaced under the influence of respiration, thereby reducing the puncture accuracy. Secondly, the puncture process lacks real-time visualization, which may potentially give rise to medical accidents. This paper presents a semi-automatic surgical robot system based on the fusion guidance of real-time ultrasound images and CT, along with the monitoring of the patient’s respiratory state, to address these issues. Method: This system utilizes a six-axis force sensor in contact with the human body, and a respiratory model can be constructed through data got from force sensor to monitor the patient’s respiratory phase and recommend the optimal puncture phase. The issue of non-real-time puncture guidance is addressed through the real-time registration and fusion of ultrasound (US) images with preoperative CT images. Results: Phantom experiments and animal experiments were carried out based on this design. The test results indicate that in these two experiments, the average fusion error between US and CT of the main tissues in the liver is within 3 mm. For puncture accuracy, in the phantom experiment, the average puncture error was 1.0 mm, with a minimum of 0 mm and a maximum of 2.1 mm. In the animal experiment, the average puncture error was 2.5 mm, ranging from a minimum of 1.6 mm to a maximum of 3.0 mm. Conclusion: The results of two experiments show both the image fusion accuracy and puncture accuracy of this system are within 3mm, which can meet the requirement of 5 mm puncture accuracy in clinical practice. Approximately 70% of the operation are automatically accomplished by robot system, greatly reducing the reliance on the doctor’s experience.
- Open Access
- 9 July 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (12) , 9228-9238
The application of avatrombopag in chronic liver disease patients with severe thrombocytopenia undergoing procedures in China: a prospective real-world cohort study
Background: Several guidelines recommend individualized treatment to correct severe thrombocytopenia before medium- to high-risk invasive procedures in patients with chronic liver disease, lowering the risk of bleeding. In this multi-center, prospective, non-randomized controlled cohort study, the efficacy and safety of avatrombopag, proven safe and effective in two phase III trials, was further evaluated in China. Materials and Methods: This real-world study enrolled 341 chronic liver disease patients with severe thrombocytopenia scheduled for medium- and high-risk invasive procedures across 20 sites between 10 June 2021 and 25 April 2023. Avatrombopag (40 mg/day or 60 mg/day, treatment group) or alternatives (rhTPO, rhIL-11, Chinese patent medicine or no medication treatment, control group) were administered based on the doctor’s and patient’s preferences. Homogeneity was compared between the two groups. Results: In the per-protocol set of 293 cases (66 patients of the treatment group, 79 female patients), the treatment group showed a higher proportion of patients not requiring transfusion or rescue treatment (90.9% vs. 63.9%, P < 0.001), exhibited more patients with a platelet count of ≥50 × 10 9 /L (78.8% vs. 23.4%, P < 0.001) and higher platelet counts [(75.6 ± 42.9) × 10 9 /L vs. (46.4 ± 23.1) × 10 9 /L, P < 0.001] on the procedure day, and demonstrated lower transfusion rates (7.6% vs. 32.9%, P < 0.001), with fewer WHO ≥ 2-grade bleeding events and comparable adverse events. Conclusion: Avatrombopag effectively raises platelet counts, mitigating the need for transfusions and lowering the bleeding events in real-world scenarios of Chinese chronic liver disease patients with severe thrombocytopenia during the peri-procedure period.
- 9 July 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (12) , 9228-9238
Open AccessThe application of avatrombopag in chronic liver disease patients with severe thrombocytopenia undergoing procedures in China: a prospective real-world cohort study
Background: Several guidelines recommend individualized treatment to correct severe thrombocytopenia before medium- to high-risk invasive procedures in patients with chronic liver disease, lowering the risk of bleeding. In this multi-center, prospective, non-randomized controlled cohort study, the efficacy and safety of avatrombopag, proven safe and effective in two phase III trials, was further evaluated in China. Materials and Methods: This real-world study enrolled 341 chronic liver disease patients with severe thrombocytopenia scheduled for medium- and high-risk invasive procedures across 20 sites between 10 June 2021 and 25 April 2023. Avatrombopag (40 mg/day or 60 mg/day, treatment group) or alternatives (rhTPO, rhIL-11, Chinese patent medicine or no medication treatment, control group) were administered based on the doctor’s and patient’s preferences. Homogeneity was compared between the two groups. Results: In the per-protocol set of 293 cases (66 patients of the treatment group, 79 female patients), the treatment group showed a higher proportion of patients not requiring transfusion or rescue treatment (90.9% vs. 63.9%, P < 0.001), exhibited more patients with a platelet count of ≥50 × 10 9 /L (78.8% vs. 23.4%, P < 0.001) and higher platelet counts [(75.6 ± 42.9) × 10 9 /L vs. (46.4 ± 23.1) × 10 9 /L, P < 0.001] on the procedure day, and demonstrated lower transfusion rates (7.6% vs. 32.9%, P < 0.001), with fewer WHO ≥ 2-grade bleeding events and comparable adverse events. Conclusion: Avatrombopag effectively raises platelet counts, mitigating the need for transfusions and lowering the bleeding events in real-world scenarios of Chinese chronic liver disease patients with severe thrombocytopenia during the peri-procedure period.
- 1 June 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 315 (3) , e243450
Diagnostic Performance of CT/MRI LI-RADS Version 2018 Major Feature Combinations: Individual Participant Data Meta-Analysis
This meta-analysis showed that most major feature combinations in the same CT/MRI Liver Imaging Reporting and Data System category had similar positive predictive values for hepatocellular carcinoma in patients at high risk for cancer, with the exception of five combinations from LR-3 to LR-5.
- 1 June 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 315 (3) , e243450
Diagnostic Performance of CT/MRI LI-RADS Version 2018 Major Feature Combinations: Individual Participant Data Meta-Analysis
This meta-analysis showed that most major feature combinations in the same CT/MRI Liver Imaging Reporting and Data System category had similar positive predictive values for hepatocellular carcinoma in patients at high risk for cancer, with the exception of five combinations from LR-3 to LR-5.
- 28 November 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (6) , 2476-2493
Non-radiomics imaging (US-CEUS) features and clinical text features: correlation with microvascular invasion and tumor grading in hepatocellular carcinoma
Objectives To predict microvascular invasion (MVI) status and tumor grading of hepatocellular carcinoma (HCC) by evaluating preoperative non-radiomics ultrasound and contrast-enhanced ultrasound (US-CEUS) features and determine the influences of MVI/tumor grading on the category of CEUS LI-RADS for HCC. Methods A total of 506 HCC patients who underwent preoperative US-CEUS examinations from 8 hospitals between July 2020 and June 2023 were enrolled. According to the MVI status, all the patients were classified, and HCC differentiation was assessed by using Edmondson-Steiner (ES) grading: MVI-negative (M0) and low-grade ES (GI/II) (MN-L, n = 297) and MVI-positive (M1/M2) and/or high-grade ES (GIII/IV) (MP-H, n = 209). Stratified analysis was performed based on fibrosis stage and tumor size. Results The results proved that MN-L HCC was more frequently classified into the LR-5 category (p = 0.034), while MP-H HCC was more frequently classified into the LR-TIV (p = 0.010). The heterogeneously arterial phase hyperenhancement (APHE) is significantly correlated with MVI(+)/high grade-ES (p = 0.003). Compared with MN-L HCC, the onset of washout was earlier, washout rate was higher, and tumor-invasion border was larger (all p < 0.01) in MP-H HCC. In addition, fibrosis stage and tumor size significantly influenced the onset of washout and washout rate of HCC (all p < 0.01). The tumor-invasion border was only positively correlated with tumor size (p < 0.001) rather than fibrosis stage (p > 0.05). Conclusions MVI status and tumor grading influence the classification of LR-5 and LR-TIV. Heterogeneous APHE, higher washout rate, earlier onset of washout (≤65 s), larger tumor-invasion border (≥3 mm) and higher alpha fetoprotein level indicate the presence of MVI and/or high-grade ES.
- 28 November 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (6) , 2476-2493
Non-radiomics imaging (US-CEUS) features and clinical text features: correlation with microvascular invasion and tumor grading in hepatocellular carcinoma
Objectives To predict microvascular invasion (MVI) status and tumor grading of hepatocellular carcinoma (HCC) by evaluating preoperative non-radiomics ultrasound and contrast-enhanced ultrasound (US-CEUS) features and determine the influences of MVI/tumor grading on the category of CEUS LI-RADS for HCC. Methods A total of 506 HCC patients who underwent preoperative US-CEUS examinations from 8 hospitals between July 2020 and June 2023 were enrolled. According to the MVI status, all the patients were classified, and HCC differentiation was assessed by using Edmondson-Steiner (ES) grading: MVI-negative (M0) and low-grade ES (GI/II) (MN-L, n = 297) and MVI-positive (M1/M2) and/or high-grade ES (GIII/IV) (MP-H, n = 209). Stratified analysis was performed based on fibrosis stage and tumor size. Results The results proved that MN-L HCC was more frequently classified into the LR-5 category (p = 0.034), while MP-H HCC was more frequently classified into the LR-TIV (p = 0.010). The heterogeneously arterial phase hyperenhancement (APHE) is significantly correlated with MVI(+)/high grade-ES (p = 0.003). Compared with MN-L HCC, the onset of washout was earlier, washout rate was higher, and tumor-invasion border was larger (all p < 0.01) in MP-H HCC. In addition, fibrosis stage and tumor size significantly influenced the onset of washout and washout rate of HCC (all p < 0.01). The tumor-invasion border was only positively correlated with tumor size (p < 0.001) rather than fibrosis stage (p > 0.05). Conclusions MVI status and tumor grading influence the classification of LR-5 and LR-TIV. Heterogeneous APHE, higher washout rate, earlier onset of washout (≤65 s), larger tumor-invasion border (≥3 mm) and higher alpha fetoprotein level indicate the presence of MVI and/or high-grade ES.
- 27 September 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (4) , 1533-1546
Is concurrent LR-5 associated with a higher rate of hepatocellular carcinoma in LR-3 or LR-4 observations? An individual participant data meta-analysis
Background The Liver Imaging Reporting and Data System (LI-RADS) does not consider factors extrinsic to the observation of interest, such as concurrent LR-5 observations. Purpose To evaluate whether the presence of a concurrent LR-5 observation is associated with a difference in the probability that LR-3 or LR-4 observations represent hepatocellular carcinoma (HCC) through an individual participant data (IPD) meta-analysis. Methods Multiple databases were searched from 1/2014 to 2/2023 for studies evaluating the diagnostic accuracy of CT/MRI for HCC using LI-RADS v2014/2017/2018. The search strategy, study selection, and data collection process can be found at https://osf.io/rpg8x. Using a generalized linear mixed model (GLMM), IPD were pooled across studies and modeled simultaneously with a one-stage meta-analysis approach to estimate positive predictive value (PPV) of LR-3 and LR-4 observations without and with concurrent LR-5 for the diagnosis of HCC. Risk of bias was assessed using a composite reference standard and Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2). Results Twenty-nine studies comprising 2591 observations in 1456 patients (mean age 59 years, 1083 [74%] male) were included. 587/1960 (29.9%) LR-3 observations in 1009 patients had concurrent LR-5. The PPV for LR-3 observations with concurrent LR-5 was not significantly different from the PPV without LR-5 (45.4% vs 37.1%, p = 0.63). 264/631 (41.8%) LR-4 observations in 447 patients had concurrent LR-5. The PPV for LR-4 observations with concurrent LR-5 was not significantly different from LR-4 observations without concurrent LR-5 (88.6% vs 69.5%, p = 0.08). A sensitivity analysis for low-risk of bias studies (n = 9) did not differ from the primary analysis. Conclusion The presence of concurrent LR-5 was not significantly associated with differences in PPV for HCC in LR-3 or LR-4 observations, supporting the current LI-RADS paradigm, wherein the presence of synchronous LR-5 may not alter the categorization of LR-3 and LR-4 observations.
- 27 September 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (4) , 1533-1546
Is concurrent LR-5 associated with a higher rate of hepatocellular carcinoma in LR-3 or LR-4 observations? An individual participant data meta-analysis
Background The Liver Imaging Reporting and Data System (LI-RADS) does not consider factors extrinsic to the observation of interest, such as concurrent LR-5 observations. Purpose To evaluate whether the presence of a concurrent LR-5 observation is associated with a difference in the probability that LR-3 or LR-4 observations represent hepatocellular carcinoma (HCC) through an individual participant data (IPD) meta-analysis. Methods Multiple databases were searched from 1/2014 to 2/2023 for studies evaluating the diagnostic accuracy of CT/MRI for HCC using LI-RADS v2014/2017/2018. The search strategy, study selection, and data collection process can be found at https://osf.io/rpg8x. Using a generalized linear mixed model (GLMM), IPD were pooled across studies and modeled simultaneously with a one-stage meta-analysis approach to estimate positive predictive value (PPV) of LR-3 and LR-4 observations without and with concurrent LR-5 for the diagnosis of HCC. Risk of bias was assessed using a composite reference standard and Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2). Results Twenty-nine studies comprising 2591 observations in 1456 patients (mean age 59 years, 1083 [74%] male) were included. 587/1960 (29.9%) LR-3 observations in 1009 patients had concurrent LR-5. The PPV for LR-3 observations with concurrent LR-5 was not significantly different from the PPV without LR-5 (45.4% vs 37.1%, p = 0.63). 264/631 (41.8%) LR-4 observations in 447 patients had concurrent LR-5. The PPV for LR-4 observations with concurrent LR-5 was not significantly different from LR-4 observations without concurrent LR-5 (88.6% vs 69.5%, p = 0.08). A sensitivity analysis for low-risk of bias studies (n = 9) did not differ from the primary analysis. Conclusion The presence of concurrent LR-5 was not significantly associated with differences in PPV for HCC in LR-3 or LR-4 observations, supporting the current LI-RADS paradigm, wherein the presence of synchronous LR-5 may not alter the categorization of LR-3 and LR-4 observations.
- 14 May 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 49 (10) , 3427-3437
A combined model based on radiomics features of Sonazoid contrast-enhanced ultrasound in the Kupffer phase for the diagnosis of well-differentiated hepatocellular carcinoma and atypical focal liver lesions: a prospective, multicenter study
Objective The objective of this study was to develop a combined model based on radiomics features of Sonazoid contrast-enhanced ultrasound (CEUS) during the Kupffer phase and to evaluate its value in differentiating well-differentiated hepatocellular carcinoma (w-HCC) from atypical benign focal liver lesions (FLLs). Methods A total of 116 patients with preoperatively Sonazoid-CEUS confirmed w-HCC or benign FLL were selected from a prospective multiple study on the clinical application of Sonazoid in FLLs conducted from August 2020 to March 2021. According to the randomization principle, the patients were divided into a training cohort and a test cohort in a 7:3 ratio. Seventy-nine patients were used for establishing and training the radiomics model and combined model. In comparison, 37 patients were used for validating and comparing the performance of the models. The diagnostic efficacy of the models for w-HCC and atypical benign FLLs was evaluated using ROCs curves and decision curves. A combined model nomogram was created to assess its value in reducing unnecessary biopsies. Results Among the patients, there were 55 cases of w-HCC and 61 cases of atypical benign FLLs, including 28 cases of early liver abscess, 16 cases of atypical hepatic hemangioma, 8 cases of hepatocellular dysplastic nodules (DN), and 9 cases of focal nodular hyperplasia (FNH). The radiomics model and combined model we established had AUCs of 0.905 and 0.951, respectively, in the training cohort, and the AUCs of the two models in the test cohort were 0.826 and 0.912, respectively. The combined model outperformed the radiomics feature model significantly. Decision curve analysis demonstrated that the combined model achieved a higher net benefit within a specific threshold probability range (0.25 to 1.00). A nomogram of the combined model was developed. Conclusion The combined model based on the radiomics features of Sonazoid-CEUS in the Kupffer phase showed satisfactory performance in diagnosing w-HCC and atypical benign FLLs. It can assist clinicians in timely detecting malignant FLLs and reducing unnecessary biopsies for benign diseases.
- 14 May 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 49 (10) , 3427-3437
A combined model based on radiomics features of Sonazoid contrast-enhanced ultrasound in the Kupffer phase for the diagnosis of well-differentiated hepatocellular carcinoma and atypical focal liver lesions: a prospective, multicenter study
Objective The objective of this study was to develop a combined model based on radiomics features of Sonazoid contrast-enhanced ultrasound (CEUS) during the Kupffer phase and to evaluate its value in differentiating well-differentiated hepatocellular carcinoma (w-HCC) from atypical benign focal liver lesions (FLLs). Methods A total of 116 patients with preoperatively Sonazoid-CEUS confirmed w-HCC or benign FLL were selected from a prospective multiple study on the clinical application of Sonazoid in FLLs conducted from August 2020 to March 2021. According to the randomization principle, the patients were divided into a training cohort and a test cohort in a 7:3 ratio. Seventy-nine patients were used for establishing and training the radiomics model and combined model. In comparison, 37 patients were used for validating and comparing the performance of the models. The diagnostic efficacy of the models for w-HCC and atypical benign FLLs was evaluated using ROCs curves and decision curves. A combined model nomogram was created to assess its value in reducing unnecessary biopsies. Results Among the patients, there were 55 cases of w-HCC and 61 cases of atypical benign FLLs, including 28 cases of early liver abscess, 16 cases of atypical hepatic hemangioma, 8 cases of hepatocellular dysplastic nodules (DN), and 9 cases of focal nodular hyperplasia (FNH). The radiomics model and combined model we established had AUCs of 0.905 and 0.951, respectively, in the training cohort, and the AUCs of the two models in the test cohort were 0.826 and 0.912, respectively. The combined model outperformed the radiomics feature model significantly. Decision curve analysis demonstrated that the combined model achieved a higher net benefit within a specific threshold probability range (0.25 to 1.00). A nomogram of the combined model was developed. Conclusion The combined model based on the radiomics features of Sonazoid-CEUS in the Kupffer phase showed satisfactory performance in diagnosing w-HCC and atypical benign FLLs. It can assist clinicians in timely detecting malignant FLLs and reducing unnecessary biopsies for benign diseases.